MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Genetics, Gene & Cell Therapy Companies
Prevail Therapeutics
Organization & Developments: Prevail Therapeutics
Parents
Prevail Therapeutics
Children
2020: Eli Lilly picks up gene therapy player Prevail in deal worth $1B+, making good on bolt-on pledge from earlier this year_endpts
and PR004 for patients with certain synucleinopathies.
PR006 for patients with frontotemporal dementia with GRNmutations (FTD-GRN)
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases.
Prevail is developing PR001 for patients with Parkinson's disease with GBA1mutations (PD-GBA) and neuronopathic Gaucher disease (nGD)
Jumps
Finance & Acquisition: Prevail Therapeutics
Key People: Prevail Therapeutics